European Pharmaceutical Review

NOVEMBER 10, 2023

According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging. The construction projects will be finalised from the end of 2025 through to 2029. Most of the investment will be focused on API capacity.

Packaging 111

Packaging Pharmaceutical Manufacturing Diabetes 111

European Pharmaceutical Review

MAY 14, 2024

At its Le Trait site in Normandy, Sanofi added that it will devote €100 million for new capacity for biologics formulation, filling, device assembly and packaging. In Lyon Gerland, Sanofi stated that it is investing €10 million to locate production of TZield ® , a biologic for type 1 diabetes, in France.

Vaccines 98

Vaccines Packaging Diabetes 98

Express Pharma

MARCH 16, 2025

and Europe held manufacturers accountable for their environmental impact, leading to an increase in partnerships with tech companies focused on sustainable packaging and production solutions. What are the top 3 trends to watch out for in 2025,which could have a disproportionate impact on the globaland Indian life sciences landscape?

Biosimilars 98

Biosimilars Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies 98

PharmaShots

FEBRUARY 1, 2023

Ximluci is expected to be available in the UK in 2023 The approval for Ximluci was granted through the EC decision reliance procedure, whereby the MHRA’s decision was based on the EC Ximluci was approved in the UK for wet AMD, DME, diabetic retinopathy, RVO, and visual impairment due to choroidal neovascularization in adults.

Biosimilars 40

Biosimilars Packaging Diabetes Hospitals 40

PharmaShots

JUNE 7, 2023

Amgen will be allowed to sell its ustekinumab biosimilar no later than Jan 2025 Amgen highlighted the preliminary results from a P-III study which showed no clinical differences b/w ABP 654 and Stelara in adults with mod. PsO Ustekinumab, an anti-IL-12/IL-23 Ab drug indicated to treat PsO, PsA, CD, and UC.

Biosimilars 40

Biosimilars Packaging Diabetes Pharmaceutical Companies 40

Ramblings of a pharmacist

JANUARY 4, 2025

This indicates its marketing name, its drug benefit type (EA = Enhanced Alternative), and its “plan code” - a combination of the Medicare Contract ID (H4604), the Plan Benefit Package (011) and the segment ID (0, though I’m still not sure what the point of this one is). of Part D beneficiaries).

Independent Pharmacies 98

Independent Pharmacies Packaging Diabetes 98